Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Imatinib AND STI571

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    50 result(s) found for: Imatinib AND STI571. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2012-002540-25 Sponsor Protocol Number: CSTI571A2406 Start Date*: 2013-02-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, multi-center imatinib roll-over protocol for patients who have completed a previous Novartis sponsored imatinib study and are judged by the investigator to benefit from continued ima...
    Medical condition: Male and female patients who are currently enrolled in a Novartis-sponsored, Oncology OGD&GMA imatinib study, are benefiting from treatment with imatinib and have fulfilled all their requirements ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001396-19 Sponsor Protocol Number: CSTI571 0109 Extension2 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: An extension to a phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive leukemia including acute lymphoblastic leukaemia, acut...
    Medical condition: Philadelphia chromosome-opositive chronic myeloid leukamia in myeloid blast crisis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001397-92 Sponsor Protocol Number: CSTI571 0110 Extension2 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: An extension to a phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha
    Medical condition: Philadelphia chromosome-opositive chronic myeloid leukamia in myeloid blast crisis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004758-34 Sponsor Protocol Number: CAMN107G2301 Start Date*: 2009-03-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tu...
    Medical condition: adult patients with histologically confirmed unresectable or metastatic GIST, either who have not received any prior anti-neoplastic therapy or, who experienced recurrence of GIST > 6 months after ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) SK (Completed) CZ (Completed) SE (Completed) HU (Completed) NL (Completed) DE (Completed) FR (Completed) IT (Completed) GB (Completed) DK (Prematurely Ended) GR (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-001805-34 Sponsor Protocol Number: CSTI571I1203 Start Date*: 2017-08-15
    Sponsor Name:Novartis Pharma K.K
    Full Title: Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
    Medical condition: Philadelphia Chromosome Positive Acute Lymphocytic Leukemia (Ph+ALL)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004774-24 Sponsor Protocol Number: CSTI571BDE57 Start Date*: 2006-03-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label multicenter phase II study of Imatinib mesylate (Glivec) treatment of patients with malignant peripheral nerve sheath tumors
    Medical condition: malignant nerve sheath tumor
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001594-24 Sponsor Protocol Number: CABL001E2201 Start Date*: 2018-10-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treat...
    Medical condition: Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed) DK (Completed) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005569-12 Sponsor Protocol Number: CSTI571E2203 Start Date*: 2006-01-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial...
    Medical condition: pulmonary arterial hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002504-15 Sponsor Protocol Number: NordCML002 Start Date*: 2004-12-01
    Sponsor Name:The Nordic CML Study Group
    Full Title: A RANDOMIZED PHASE II STUDY COMPARING IMATINIB AND THE COMBINATION OF IMATINIB AND PEGYLATED INTERFERON ALPHA-2B IN NEWLY DIAGNOSED NON-HIGH RISK CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE HEMAT...
    Medical condition: Newly diagnosed chronic myeloid leukemia (CML) belonging to intermedia (IR) or low risk (LR) by the Sokal prognostic score
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003166-42 Sponsor Protocol Number: CSTI571BDE55 Start Date*: 2005-12-27
    Sponsor Name:University of Leipzig
    Full Title: Palliative Chemotherapy (2nd line) with Imatinib (GlivecTM) in Patients with Bile Duct Cancer.
    Medical condition: Patients with histologically proven adenocarcinoma of the gallbladder/bile duct (not papillary cancer) in an advanced stage, who have not responded to a first line chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10004585 Bile duct adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004063-29 Sponsor Protocol Number: CSTI571BDE40 Start Date*: 2004-12-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Glivec (imatinib mesylate) in combination with hydroxyurea or hydroxyurea alone as an oral therapy in temozolomide resistant progressive glioblastoma patients
    Medical condition: Glioblastoma multiforme/astrocytoma WHO grade IV, with progression on temozolomide containing regimen
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007054-35 Sponsor Protocol Number: CAMN107A2404 Start Date*: 2009-08-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A RANDOMIZED PHASE III STUDY OF IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIB
    Medical condition: IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CML AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIB
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2004-000881-10 Sponsor Protocol Number: CSTI571AAT06 Start Date*: 2005-03-08
    Sponsor Name:CELSG (Central European Leukemia Study Group)
    Full Title: International, multicenter, randomised, open-labeled, 2-arm - Phase III Study comparing Imatinib (STI571, Glivec®) Standard Dose (400 mg/day) with Imatinib High Dose Induction (800 mg/day) followed...
    Medical condition: patients with chronic myelogenous leukemia in chronic phase (Ph+/BCR-ABL+)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002600-41 Sponsor Protocol Number: CSTI571H2201 Start Date*: 2006-01-17
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio fase II, abierto, multicéntrico, no comparativo, que evalúa la eficacia de Glivec® con Hidroxiurea en pacientes con Glioblastoma Multiforme (GBM) en progresión, que no reciben fármacos anti...
    Medical condition: Glioblastoma multiforme progresivo (GBM) tras fallo a terapia de primera línea definida por cirugía, radioterapia y exposición a un régimen de quimioterapia de Temozolamida (TMZ).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002603-16 Sponsor Protocol Number: CSTI571H2202 Start Date*: 2006-01-17
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio fase II, abierto, multicéntrico, no comparativo, que evalúa la eficacia de Glivec® con Hidroxiurea en pacientes con Glioblastoma Multiforme (GBM) en progresión, que reciben fármacos anticon...
    Medical condition: Glioblastoma multiforme progresivo (GBM) tras fallo a terapia de primera línea definida por cirugía, radioterapia y exposición a un régimen de quimioterapia de Temozolamida (TMZ).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001362-40 Sponsor Protocol Number: CSTI571BIT15 Start Date*: 2004-07-22
    Sponsor Name:NOVARTIS FARMA
    Full Title: PHASE II STUDY OF IMATINIB MESYLATE IN CHORDOMA
    Medical condition: Treatment of advanced or unresectable chordoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10008747 PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000208-34 Sponsor Protocol Number: CAMN107A2303 Start Date*: 2007-06-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III multi-center, open label, randomised study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chr...
    Medical condition: Adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009015 Chronic myeloid leukemia LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) BE (Completed) IT (Completed) ES (Completed) SK (Completed) AT (Completed) FR (Completed) NL (Completed) FI (Completed) DK (Completed) DE (Completed) PT (Prematurely Ended) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002267-11 Sponsor Protocol Number: CAMN107A2201 Start Date*: 2006-11-10
    Sponsor Name:Novartis Pharma Services
    Full Title: A randomized, open-label,multi-center study to evaluate the efficacy of nilotinib versus imatinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and resistant/intolera...
    Medical condition: Gastrointestinal stromal tumors (GIST)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) BE (Completed) FR (Completed) IT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-001804-31 Sponsor Protocol Number: CSTI571AJP02 Start Date*: 2017-08-10
    Sponsor Name:Novartis Pharma K.K
    Full Title: Ph3 trial of Glivec in CML-CP patients previously untreated with IFN-alfa
    Medical condition: CML-CP patients
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-001980-41 Sponsor Protocol Number: CSTI571BDE66 Start Date*: 2007-02-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Glivec® (imatinib mesylate)/Litalir® (hydroxyurea) plus initial radiotherapy after surgery in patients with newly diagnosed glioblastoma multiforme followed by Glivec® and Litalir® – A phase I/II s...
    Medical condition: Glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 08 06:23:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA